Volume 26, Issue 5 e14295
BRIEF COMMUNICATION

Protein-losing enteropathy recurrence after pediatric heart transplantation: Multicenter case series

Ezequiel Sagray

Ezequiel Sagray

Division of Pediatric Cardiology, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA

Search for more papers by this author
Jonathan N. Johnson

Jonathan N. Johnson

Division of Pediatric Cardiology, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA

Search for more papers by this author
Kurt R. Schumacher

Kurt R. Schumacher

Division of Pediatric Cardiology, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA

Search for more papers by this author
Shawn West

Shawn West

Pediatric Cardiology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA

Search for more papers by this author
Ray E. Lowery

Ray E. Lowery

Division of Pediatric Cardiology, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA

Search for more papers by this author
Kathleen Simpson

Corresponding Author

Kathleen Simpson

Division of Cardiology, Department of Pediatrics, Children's Hospital of Colorado, University of Colorado Denver, Aurora, Colorado, USA

Correspondence

Kathleen Simpson, Division of Cardiology, Department of Pediatrics, Children's Hospital of Colorado, University of Colorado, 13123 East 16th Avenue, Aurora, CO 80045, USA.

Email: [email protected]

Search for more papers by this author
First published: 21 April 2022
Citations: 6

Abstract

Background

Protein-losing enteropathy (PLE) is a devastating complication of the Fontan circulation. Although orthotopic heart transplantation (HTx) typically results in resolution of PLE symptoms, isolated cases of PLE relapse have been described after HTx.

Methods

Patients with Fontan-related PLE who had undergone HTx at participating centers and experienced relapse of PLE during follow-up were retrospectively identified. Available data related to pre- and post-HTx characteristics and PLE events were collected.

Results

Eight patients from four different centers were identified. Median time from Fontan procedure to the development of PLE was 8 years, and median age at HTx was 17 years (range 7.7–21). In all patients, PLE resolved at a median time of 1 month after HTx (0.3–5). PLE recurrences occurred at a median time of 7.5 months after HTx (2–132). Each occurrence was associated with one or more significant clinical events; most commonly cellular- or antibody-mediated rejection; and less commonly graft dysfunction, infection, thrombosis, and posttransplant lymphoproliferative disease. PLE recurrences resolved after the successful treatment of the concomitant event, after a median time of 2 months in seven cases, while persisted and recurred in one patient in association with atypical mycobacterium infection and subsequent PTLD onset and relapses. Six patients were alive during follow-up at a median time of 4 years (1.3–22.5) after HTx.

Conclusions

This is the largest series of PLE recurrence after HTx. All cases were associated with one or more concomitant and significant clinical events. PLE typically resolved after resolution of the inciting clinical event.

CONFLICT OF INTEREST

Authors have no interests to disclose.

DATA AVAILABILITY STATEMENT

The data used to support the findings of this study are included within the article.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.